Relationship among adiponectin, insulin resistance and atherosclerosis in non-diabetic hypertensive patients and healthy adults

References

• Koleva DI, Orbetzova MM, Nikolova JG, Deneva TI. Pathophysiological role of adiponectin, leptin and asymmetric dimethylarginine in the process of atherosclerosis. Folia Med (Plovdiv) 2016;58:234–40.
   PubMedGoogle Scholar
• Seino Y, Hirose H, Saito I, Itoh H. High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism 2009;58:355–60.
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Jama 2004;291:1730–37.
   PubMed Web of Science ®Google Scholar
• Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 2017;18:1321.
   PubMed Web of Science ®Google Scholar
• Balsan GA, Vieira JL, Oliveira AM, Portal VL. Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras 1992;2015(61):72–80.
   Google Scholar
• Dobiasova M. [AIP–atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice]. Vnitr Lek 2006;52:64–71.
   PubMedGoogle Scholar
• Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873–80.
   PubMed Web of Science ®Google Scholar
• Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–53.
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–99.
   PubMed Web of Science ®Google Scholar
• Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91:258S–261S.
   PubMed Web of Science ®Google Scholar
• Ding Y, Li S, Ma RL, Guo H, Zhang J, Zhang M, Liu J, Guo S. Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome. Clin Biochem 2015;48:503–07.
   PubMed Web of Science ®Google Scholar
• Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici M, et al. The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 2014;51:123–31.
   PubMed Web of Science ®Google Scholar
• Chedraui P, Perez-Lopez FR, Escobar GS, Palla G, Montt-Guevara M, Cecchi E, Genazzani AR, Simoncini T. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas 2014;79:86–90.
   PubMed Web of Science ®Google Scholar
• Whitworth JA. World health organization (WHO)/International society of hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92.
   PubMed Web of Science ®Google Scholar
• Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320–25.
   PubMed Web of Science ®Google Scholar
• Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K. Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003;26:705–10.
   PubMed Web of Science ®Google Scholar
• Della Mea P, Lupia M, Bandolin V, Guzzon S, Sonino N, Vettor R, Fallo F. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005;18:30–35.
   PubMed Web of Science ®Google Scholar
• Shim CY, Park S, Kim JS, Shin DJ, Ko YG, Kang SM, Choi D, Ha JW, Jang Y, Chung N. Association of plasma retinol-binding protein 4, adiponectin, and high molecular weight adiponectin with insulin resistance in non-diabetic hypertensive patients. Yonsei Med J 2010;51:375–84.
   PubMed Web of Science ®Google Scholar
• Peer M, Mashavi M, Matas Z, Harpaz D, Shargorodsky M. Adiponectin as an independent predictor of left ventricular hypertrophy in nondiabetic patients with hypertension. Angiology 2015;66:219–24.
   PubMed Web of Science ®Google Scholar
• Hansen T, Ahlstrom H, Soderberg S, Hulthe J, Wikstrom J, Lind L, Johansson L. Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population. Atherosclerosis 2009;205:163–67.
   PubMed Web of Science ®Google Scholar
• Nilsson PM, Engstrom G, Hedblad B, Frystyk J, Persson MM, Berglund G, Flyvbjerg A. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006;26:2758–62.
   PubMed Web of Science ®Google Scholar
• Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85–89.
   PubMed Web of Science ®Google Scholar
• Steffes MW, Gross MD, Lee DH, Schreiner PJ, Jacobs DR Jr. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the coronary artery risk development in young adults study. Obesity (Silver Spring) 2006;14:319–26.
   PubMed Web of Science ®Google Scholar
• Chen MC, Lee CJ, Yang CF, Chen YC, Wang JH, Hsu BG. Low serum adiponectin level is associated with metabolic syndrome and is an independent marker of peripheral arterial stiffness in hypertensive patients. Diabetol Metab Syndr 2017;9:49.
   PubMed Web of Science ®Google Scholar
• Juarez-Rojas JG, Posadas-Sanchez R, Martinez-Alvarado MDR, Torres-Tamayo M, Jorge-Galarza E, Mancilla-Valenzuela EY, Posadas-Romero C, Cardoso-Saldana GC, Gonzalez-Salazar MDC, Vargas-Alarcon G, et al. Association of adiponectin with subclinical atherosclerosis in a Mexican-Mestizo population. Arch Med Res 2017;48:73–78.
   PubMed Web of Science ®Google Scholar
• Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, Hamazaki Y, Suzuki H, Itoh Y, Katagiri T, et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. J Atheroscler Thromb 2014;21:755–67.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol 2014;34:1069–77.
   PubMed Web of Science ®Google Scholar
• Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine (Baltimore) 2017;96:e8058.
   PubMed Web of Science ®Google Scholar
• Bendzala M, Sabaka P, Caprnda M, Komornikova A, Bisahova M, Baneszova R, Petrovic D, Prosecky R, Rodrigo L, Kruzliak P, et al. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women: A 10-year follow-up. Wien Klin Wochenschr 2017;129:793–98.
   PubMed Web of Science ®Google Scholar
• Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic index of plasma and triglyceride/high-density lipoprotein cholesterol ratio predict mortality risk better than individual cholesterol risk factors, among an older adult population. Mayo Clin Proc 2017;92:680–81.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–301.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752–61.
   PubMed Web of Science ®Google Scholar
• Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, Fu Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 2010;59:791–99.
   PubMed Web of Science ®Google Scholar
• Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975–81.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–46.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332–39.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Horm Mol Biol Clin Investig 2014;19:75–88.
   PubMedGoogle Scholar
• Viveros MP, De Fonseca FR, Bermudez-Silva FJ, McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008;8:220–30.
   PubMedGoogle Scholar
• Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319–26.
   PubMed Web of Science ®Google Scholar